Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech has signed a licensing agreement with Novartis for conformationally restricted nucleotide (CRN) technology for the development of both single- and double-stranded oligonucleotide therapeutics.
Subscribe to our email newsletter
According to the non-exclusive license agreement, Marina will receive $1m upfront payment.
Marina Biotech president and chief executive officer Michael French said Marina’s CRN is quite versatile and can be used to create stable, highly active oligonucleotide therapeutics and, in particular, both single- and double-stranded oligos.
"We view this license as yet another important validation of our nucleic acid-based drug discovery," French added.
Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking.